Global Life Science Ventures Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Text size

History

Founded in 1996, GLSV was one of the first European venture capital firms to focus exclusively on the life science industry. The fund was initiated through the support of Dr Stefan Engelhorn (the Engelhorn family was the original owner of Boehringer Mannheim). HypoVereinsbank Group and ING Barings acted as cosponsors. While concentrating on building its track record in the German-speaking home markets, GLSV from the beginning has also pursued international partnering opportunities, including investments in the United States.

In 2002, GLSV announced the successful completion of the financing of its second fund. The new fund of Euro 143 million met the projected target by more than doubling the size of its predecessor. Reflecting their confidence in the long-term business strategy and success of the partnership, all existing investors renewed their financial commitment to the fund. The second fund is supporting both new investments and the planned expansion in Europe. The stepwise growth of GLSV is designed to improve further the standard of service GLSV offers its clients.